# KEYVIBE-008 (MK-7684A): what clinicians are saying

> 83 statements from 21 sources (1 video, 16 posts, 2 papers, 2 registry records), 46 of them from 11 confirmed clinicians, each linked to its source. Commentary checked Nov 15, 2026.

## Report

- Trial: A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)
- NCT ID: NCT05224141
- Registry: https://clinicaltrials.gov/study/NCT05224141
- Sponsor: Merck Sharp & Dohme LLC
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: MK-7684A
- Indication: first-line extensive-stage small cell lung cancer
- Version: v1.1.0, edition 2
- Accepted: 2026-11-15 UTC
- Last checked: 2026-11-15 UTC
- Release hash: e1c9f3a60fa52841d657515551a268b516a9d7cc04cdaf5e30a45f108209d725

## Counts

- Commentary sources screened: 44
- Sources cited by verified statements: 21
- Verified statements: 83
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 46
- Findings: 10
- Named people in screened sources (unnamed speakers and accounts not counted): 16
- Speakers cited: 16
- Cited speakers with a verified identity: 12
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 11
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 11
- By role and specialty (the abstract's specialty counts):
  - 8 physician, Medical oncology
  - 3 physician, specialty not confirmed
- Organisational or shared accounts (not counted as people): 3

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

KEYVIBE-008 leads a medical oncologist to question whether pembrolizumab could be worse than atezolizumab if TIGIT blockade adds no benefit. A physician doubts that interpretation and relays speculation that toxicity-related discontinuation may have shortened pembrolizumab exposure; neither explanation is demonstrated. Another medical oncologist criticizes the combination for adding toxicity, but these negative assessments do not establish that all anti-TIGIT combinations lack benefit.

## Question clinicians left open

In KEYVIBE-008 for first-line extensive-stage small-cell lung cancer, what do clinicians say could distinguish pembrolizumab efficacy from toxicity-related shortening of pembrolizumab exposure as possible explanations for overall-survival findings with vibostolimab–pembrolizumab plus chemotherapy versus atezolizumab plus chemotherapy?

From finding F1 (6 statements from 3 speakers in 2 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Clinicians debate whether pembrolizumab itself explains the combination's outcome
  - 6 statements from 3 speakers in 2 sources.
  - 3 of the report's 11 cited clinicians.
- F2. Clinicians read KEYVIBE-008 as an unsuccessful combination with added toxicity
  - 14 statements from 7 speakers in 9 sources.
  - 4 of the report's 11 cited clinicians.
- F3. One X account questions the comparator logic; one clinician questions the supporting evidence
  - 8 statements from 4 speakers in 4 sources, 1 of them a podcast or video.
  - 2 of the report's 11 cited clinicians.
- F4. A trial-network account emphasizes referrals; relayed company statements describe a treatment-transition option
  - 7 statements from 1 speaker in 5 sources.
  - No named clinician · accounts and unnamed speakers.
- F5. One clinician, described in the source as an author of the results, values rigorous reporting
  - 4 statements from 2 speakers in 4 sources.
  - 1 of the report's 11 cited clinicians.
- F7. One X account challenges benign TIGIT safety; another ranks GALAXIES more favorably
  - 4 statements from 1 speaker in 4 sources.
  - No named clinician · accounts and unnamed speakers.
- F8. Clinicians discuss small-cell treatment despite cytopenias, with conditional adjustments and support; one addresses access-dependent immunotherapy timing and disease-related liver dysfunction.
  - 9 statements from 3 speakers in 1 source, a podcast or video.
  - 3 of the report's 11 cited clinicians.
- F9. One speaker finds choosing between established first-line regimens difficult
  - 8 statements from 2 speakers in 3 sources, 1 of them a podcast or video.
  - 2 of the report's 11 cited clinicians.

### Beyond the trial population

- F6. Clinicians ask whether anti-TIGIT enrollment and development should continue
  - 7 statements from 5 speakers in 5 sources, 1 of them a podcast or video.
  - 5 of the report's 11 cited clinicians.
- F10. One speaker asks whether inflamed or YAP1-positive data are ready to justify a phenotype-selected immunotherapy trial
  - 12 statements from 1 speaker in 1 source, a podcast or video.
  - 1 of the report's 11 cited clinicians.

2 of the 10 findings and 18 of the 83 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 6 | 7 | 2 | 3 | 3 |
| F2 | 14 | 13 | 9 | 7 | 3 |
| F3 | 8 | 8 | 4 | 4 | 3 |
| F4 | 7 | 5 | 5 | 1 | 3 |
| F5 | 4 | 4 | 4 | 2 | 2 |
| F7 | 4 | 7 | 4 | 1 | 3 |
| F8 | 9 | 6 | 1 | 3 | 3 |
| F9 | 8 | 7 | 3 | 2 | 3 |
| F6 | 7 | 6 | 5 | 5 | 3 |
| F10 | 12 | 5 | 1 | 1 | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 2 | 2 | 0 | 0 | 2 | 7 | 2 | 1 post or article, 1 publication |
| F2 | 7 | 0 | 0 | 0 | 7 | 15 | 3 | 8 posts and articles, 1 publication |
| F3 | 4 | 1 | 0 | 1 | 2 | 9 | 0 | 2 posts and articles, 1 podcast or video, 1 registry |
| F4 | 0 | 0 | 1 | 0 | 6 | 8 | 0 | 3 posts and articles, 2 registry |
| F5 | 3 | 0 | 0 | 0 | 1 | 4 | 0 | 3 posts and articles, 1 registry |
| F7 | 1 | 0 | 0 | 2 | 1 | 6 | 1 | 3 posts and articles, 1 publication |
| F8 | 6 | 0 | 2 | 1 | 0 | 12 | 0 | 1 podcast or video |
| F9 | 4 | 0 | 0 | 1 | 3 | 8 | 0 | 1 post or article, 1 podcast or video, 1 registry |
| F6 | 2 | 4 | 0 | 0 | 1 | 7 | 0 | 4 posts and articles, 1 podcast or video |
| F10 | 9 | 3 | 0 | 0 | 0 | 13 | 0 | 1 podcast or video |

### Trial dimensions

- Primary endpoint: Overall Survival (OS): F1 (4 shared claims), F2 (7 shared claims), F7 (1 shared claims)
- Secondary endpoints: F2 (1 shared claims), F5 (1 shared claims)
- Population and setting: F4 (1 shared claims), F8 (6 shared claims), F9 (1 shared claims)
- The comparison: F1 (1 shared claims), F3 (2 shared claims), F8 (1 shared claims), F9 (3 shared claims)
- Safety and tolerability: F1 (2 shared claims), F2 (6 shared claims), F7 (3 shared claims)
- Design and conduct: F3 (3 shared claims), F4 (3 shared claims), F5 (1 shared claims)

## Abbreviations

- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival
- SCLC: small cell lung cancer

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 13 sections | Paid |
| Verified statements with short source quotes and links | 83 | Paid |
| Who said each statement: the cited speakers | 16 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 11 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 12 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 21 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 11 of the 16 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Survival (OS) | discussed | 10 | 7 |
| Secondary endpoints | discussed | 2 | 2 |
| Population and setting | discussed | 8 | 2 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 6 | 3 |
| Safety and tolerability | discussed | 10 | 9 |
| Design and conduct | discussed | 7 | 6 |
| Whether pembrolizumab or toxicity-related exposure explains the combination's outcome | discussed | 4 | 1 |
| Treatment transition, continued access and historical referrals | discussed | 5 | 3 |
| Evidence thresholds, enrollment ethics and program-level implications | discussed | 15 | 7 |
| Cross-program TIGIT safety interpretations | discussed | 3 | 3 |
| Reporting an unsuccessful study and sustaining research | discussed | 3 | 3 |
| Routine-care adaptation, supportive care and immunotherapy access | discussed | 9 | 1 |
| First-line SCLC alternatives and the rationale for the atezolizumab comparator | discussed | 8 | 2 |
| Molecular-subtype selection for first-line immunotherapy | discussed | 13 | 2 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 30 statements · 36%** | | | |
| YouTube | 30 | 1 | 1 |
| **Posts · 37 statements · 45%** | | | |
| X threads | 35 | 15 | 41 |
| LinkedIn posts | 2 | 1 | 1 |
| Bluesky threads | 0 | 0 | 1 |
| **Primary sources · 16 statements · 19%** (cited for context, not screened) | | | |
| Registry (primary source, cited for context) | 12 | 2 | not screened |
| Publications (primary source, cited for context) | 4 | 2 | not screened |

- Screened window: 2022-02-04 to 2026-10-27
- Cited window: 2022-03-30 to 2026-10-21
- Retrieved: 2026-11-15

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)
- Registry: NCT05224141 (https://clinicaltrials.gov/study/NCT05224141)
- Study IDs: 7684A-008 · MK-7684A-008 (MSD) · KEYVIBE-008 (MSD) · jRCT2021220008 (jRCT) · 2023-503517-30-00 (EU CT) · U1111-1287-4436 (UTN) · 2021-005034-42
- Sponsor: Merck Sharp & Dohme LLC
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 460 (actual)
- Start: 2022-03-24 (actual)
- Primary completion: 2024-06-04 (actual)
- Primary endpoint: Overall Survival (OS) (Up to approximately 25 months)
- Intervention: Pembrolizumab/Vibostolimab Co-Formulation (biological)
- Intervention: Saline placebo (drug)
- Intervention: Etoposide (drug)
- Intervention: Cisplatin (drug)
- Intervention: Atezolizumab (biological)
- Intervention: Carboplatin (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on long-term survival expectations with first-line chemoimmunotherapy versus chemotherapy in extensive-stage small-cell lung cancer; a view on dual checkpoint blockade as first-line treatment for extensive-stage small cell lung cancer; a view on survival-endpoint limitations when interpreting durable responses to first-line chemoimmunotherapy in extensive-stage small-cell lung cancer; a view on TIGIT inhibition as a treatment strategy in first-line extensive-stage small cell lung cancer.
- 48 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 28 sources about other trials or topics are not included.
- The sources reviewed provide qualitative views, not a representative sample of HCP opinion or a measure of consensus. Reposts and repeated company quotations can amplify one original statement.
- Discussion that does not name the trial, uses other terminology or appears outside the reviewed channels may be missing.
- Some named accounts do not have an established clinical role in the sources reviewed. Their statements should not be treated as verified HCP assessments.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The interim combination comparison does not isolate pembrolizumab, vibostolimab or toxicity-related exposure as the cause of the outcome. The proposed explanations remain conditional or speculative.
- Cross-study safety rankings and historical survival comparisons are not head-to-head evidence.
- Historical recruitment communications do not establish current availability. Offering atezolizumab does not establish that a patient received it, and continued study access had specific benefit and access conditions.
- The amended protocol stopped further efficacy and survival follow-up and restricted further patient-reported-outcome analysis. A speaker's description of quality-of-life coverage is not reconciled with the amended registry's reporting restriction.
- The molecular-subtype discussion is exploratory, retrospective and limited to the first-line analyses discussed. It does not establish a validated predictive marker for MK-7684A.
- Product information was incomplete for the co-formulation and saline placebo, so the report does not provide an independent label-status assessment.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.1.0, edition 2, accepted 2026-11-15 UTC: current edition
- v1.0.0, edition 1: replaced by edition 2

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-15 UTC. No changes.

## Offer

- Size: Focused · 83 verified statements · 46 from 11 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (12 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/keyvibe-008-nct05224141
- Agents: POST https://www.erudio.com/api/orders with {"report": "keyvibe-008-nct05224141", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=keyvibe-008-nct05224141

## Cite

Erudio Health. KEYVIBE-008 (NCT05224141): HCP commentary report. Edition 2, v1.1.0. Accepted Nov 15, 2026. https://www.erudio.com/reports/keyvibe-008-nct05224141

## Questions

### How much does the KEYVIBE-008 report cost?

One edition costs $750 (Focused · 83 verified statements · 46 from 11 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the KEYVIBE-008 report cover?

83 statements from 21 sources (1 video, 16 posts, 2 papers, 2 registry records), 46 of them from 11 confirmed clinicians, each linked to its source. Commentary checked Nov 15, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the KEYVIBE-008 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "keyvibe-008-nct05224141" }) previews it and create_order({ "report": "keyvibe-008-nct05224141", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the KEYVIBE-008 report?

Edition 2 (version 1.1.0), accepted Nov 15, 2026 UTC; last checked for new commentary Nov 15, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/keyvibe-008-nct05224141.json
- Markdown: https://www.erudio.com/reports/keyvibe-008-nct05224141.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/keyvibe-008-nct05224141/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "keyvibe-008-nct05224141"}`
